Marvel Biosciences Corp. MRVL.V
TSX
| 04/30/2026 | 01/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 7.78% | 28.76% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 33.98% | 1.59% | |||
| Operating Income | -33.98% | -1.59% | |||
| Income Before Tax | 249.39% | 13.54% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 249.39% | 13.54% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 249.39% | 13.54% | |||
| EBIT | -33.98% | -1.59% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 240.54% | 15.91% | |||
| Normalized Basic EPS | 126.09% | 17.86% | |||
| EPS Diluted | 240.54% | 15.91% | |||
| Normalized Diluted EPS | 126.09% | 17.86% | |||
| Average Basic Shares Outstanding | 6.15% | 4.36% | |||
| Average Diluted Shares Outstanding | 6.15% | 4.36% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||